{"title":"沙丁胺醇雾化治疗新生儿短暂性呼吸急促：一项随机对照试验。","authors":"Aditi Dhaka, Sonu Kumar, Poonam Singh, Mayank Priyadarshi, Suman Chaurasia, Nowneet Kumar Bhat, Sriparna Basu","doi":"10.1038/s41372-024-02201-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy of nebulized salbutamol in reducing respiratory distress in late preterm and term neonates with transient tachypnea of newborn (TTN).</p><p><strong>Study design: </strong>Double-blind, placebo-controlled randomized trial.</p><p><strong>Methods: </strong>Neonates with TTN (n = 134) were allocated to nebulized salbutamol (n = 67) versus placebo (normal saline) (n = 67). The primary outcome was the duration of tachypnea (respiratory rate >60/min). Secondary outcomes were maximum Downes score and fraction of inspired oxygen (FiO<sub>2</sub>) after nebulization, duration of respiratory support, and adverse effects of salbutamol nebulization.</p><p><strong>Results: </strong>Median duration of tachypnea was 12.5 (10-16) vs. 12 (10.4-14) hours in salbutamol and placebo groups, respectively; p = 0.489. Almost all neonates received positive-pressure respiratory support at delivery room and subsequently. Maximum Downe's score, FiO<sub>2</sub> requirement, and duration of respiratory support were similar. No adverse effect of salbutamol was documented.</p><p><strong>Conclusion: </strong>There was no difference in the duration of tachypnea with nebulized salbutamol compared to placebo in late preterm and term neonates with TTN.</p><p><strong>Clinical trial registration: </strong>Clinical trial registry of India, Registration no: CTRI/2023/05/052441, Registered prospectively on 10/05/2023, https://ctri.icmr.org.in/.</p>","PeriodicalId":16690,"journal":{"name":"Journal of Perinatology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nebulized salbutamol for the treatment of transient tachypnea of the newborn: a randomized controlled trial.\",\"authors\":\"Aditi Dhaka, Sonu Kumar, Poonam Singh, Mayank Priyadarshi, Suman Chaurasia, Nowneet Kumar Bhat, Sriparna Basu\",\"doi\":\"10.1038/s41372-024-02201-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To compare the efficacy of nebulized salbutamol in reducing respiratory distress in late preterm and term neonates with transient tachypnea of newborn (TTN).</p><p><strong>Study design: </strong>Double-blind, placebo-controlled randomized trial.</p><p><strong>Methods: </strong>Neonates with TTN (n = 134) were allocated to nebulized salbutamol (n = 67) versus placebo (normal saline) (n = 67). The primary outcome was the duration of tachypnea (respiratory rate >60/min). Secondary outcomes were maximum Downes score and fraction of inspired oxygen (FiO<sub>2</sub>) after nebulization, duration of respiratory support, and adverse effects of salbutamol nebulization.</p><p><strong>Results: </strong>Median duration of tachypnea was 12.5 (10-16) vs. 12 (10.4-14) hours in salbutamol and placebo groups, respectively; p = 0.489. Almost all neonates received positive-pressure respiratory support at delivery room and subsequently. Maximum Downe's score, FiO<sub>2</sub> requirement, and duration of respiratory support were similar. No adverse effect of salbutamol was documented.</p><p><strong>Conclusion: </strong>There was no difference in the duration of tachypnea with nebulized salbutamol compared to placebo in late preterm and term neonates with TTN.</p><p><strong>Clinical trial registration: </strong>Clinical trial registry of India, Registration no: CTRI/2023/05/052441, Registered prospectively on 10/05/2023, https://ctri.icmr.org.in/.</p>\",\"PeriodicalId\":16690,\"journal\":{\"name\":\"Journal of Perinatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Perinatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41372-024-02201-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41372-024-02201-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Nebulized salbutamol for the treatment of transient tachypnea of the newborn: a randomized controlled trial.
Objective: To compare the efficacy of nebulized salbutamol in reducing respiratory distress in late preterm and term neonates with transient tachypnea of newborn (TTN).
Study design: Double-blind, placebo-controlled randomized trial.
Methods: Neonates with TTN (n = 134) were allocated to nebulized salbutamol (n = 67) versus placebo (normal saline) (n = 67). The primary outcome was the duration of tachypnea (respiratory rate >60/min). Secondary outcomes were maximum Downes score and fraction of inspired oxygen (FiO2) after nebulization, duration of respiratory support, and adverse effects of salbutamol nebulization.
Results: Median duration of tachypnea was 12.5 (10-16) vs. 12 (10.4-14) hours in salbutamol and placebo groups, respectively; p = 0.489. Almost all neonates received positive-pressure respiratory support at delivery room and subsequently. Maximum Downe's score, FiO2 requirement, and duration of respiratory support were similar. No adverse effect of salbutamol was documented.
Conclusion: There was no difference in the duration of tachypnea with nebulized salbutamol compared to placebo in late preterm and term neonates with TTN.
Clinical trial registration: Clinical trial registry of India, Registration no: CTRI/2023/05/052441, Registered prospectively on 10/05/2023, https://ctri.icmr.org.in/.
期刊介绍：
The Journal of Perinatology provides members of the perinatal/neonatal healthcare team with original information pertinent to improving maternal/fetal and neonatal care. We publish peer-reviewed clinical research articles, state-of-the art reviews, comments, quality improvement reports, and letters to the editor. Articles published in the Journal of Perinatology embrace the full scope of the specialty, including clinical, professional, political, administrative and educational aspects. The Journal also explores legal and ethical issues, neonatal technology and product development.
The Journal’s audience includes all those that participate in perinatal/neonatal care, including, but not limited to neonatologists, perinatologists, perinatal epidemiologists, pediatricians and pediatric subspecialists, surgeons, neonatal and perinatal nurses, respiratory therapists, pharmacists, social workers, dieticians, speech and hearing experts, other allied health professionals, as well as subspecialists who participate in patient care including radiologists, laboratory medicine and pathologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
